Edition:
United States

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

31.73USD
--
Change (% chg)

-- (--)
Prev Close
$31.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,339,938
52-wk High
$33.77
52-wk Low
$25.25

Latest Key Developments (Source: Significant Developments)

Genentech says FDA grants breakthrough therapy designation for Rituximab in Pemphigus Vulgaris
1:00am EDT 

Genentech: FDA grants breakthrough therapy designation for Rituxan (rituximab) in Pemphigus Vulgaris .U.S. Food and drug administration (fda) has granted breakthrough therapy designation status to Rituxan.  Full Article

Chugai Pharmaceutical to issue 123,000 shares for 469.9 mln yen
Thursday, 23 Mar 2017 04:05am EDT 

Chugai Pharmaceutical Co Ltd <4519.T>:Says it plans to issue 123,000 shares for 469.9 million yen in total.  Full Article

Roche Diagnostics Canada says Health Canada has approved cobas EGFR mutation test v2
Tuesday, 14 Mar 2017 09:49am EDT 

Roche Diagnostics Canada - :Health Canada has approved cobas EGFR mutation test v2.  Full Article

Mylan reports global settlement, license agreements with Genentech, Roche
Monday, 13 Mar 2017 08:00am EDT 

Mylan NV : Mylan announces global settlement and license agreements with Genentech and Roche on herceptin . Mylan NV- all other terms and conditions of settlement and license agreement are confidential . Mylan NV- has agreed to withdraw its pending inter partes review challenges against two U.S. Genentech patents as part of settlement . Mylan NV- licenses pertain to all countries except Japan, Brazil and Mexico . Mylan NV- settlement also eliminates further patent litigation expenses associated with Genentech and Roche .Mylan NV- has agreed to terms of a global settlement with Genentech, Inc. And F. Hoffmann-La Roche Ltd. in relation to patents for herceptin.  Full Article

Exelixis announces clinical trial collaboration with Roche
Monday, 27 Feb 2017 06:59am EST 

Exelixis Inc : Exelixis announces clinical trial collaboration with Roche to evaluate cabozantinib and atezolizumab in locally advanced or metastatic solid tumors . Exelixis Inc - expect to begin patient enrollment mid-year 2017 .Exelixis - study will evaluate potential of this combination in multiple solid tumors, including advanced renal cell carcinoma, urothelial carcinoma.  Full Article

Roche says Alecensa approved in EU for lung cancer
Tuesday, 21 Feb 2017 01:00am EST 

Roche Holding Ag : Says receives eu approval of alecensa (alectinib) for people with previously treated alk-positive non-small cell lung cancer Further company coverage: [ROG.S] (Reporting By Zurich newsroom) ((zurich.newsroom@thomsonreuters.com; +41 58 306 7336;)).  Full Article

Roche Holding reports 8.5pct passive stake in Senseonics Holdings as of Dec 31 - SEC Filing
Tuesday, 7 Feb 2017 04:50pm EST 

Senseonics Holdings Inc :Roche Holding Ltd reports 8.5% passive stake in Senseonics Holdings Inc as of December 31, 2016 - SEC Filing.  Full Article

Roche Canada says Health Canada approves Gazyva
Tuesday, 7 Feb 2017 07:30am EST 

Roche Holding AG - :Roche Canada - Health Canada approves Gazyva for patients with previously treated follicular lymphoma.  Full Article

Roche’s Herceptin approved in subcutaneous form in Switzerland
Monday, 6 Feb 2017 01:06am EST 

Roche Holding Ag :Roche media release: subcutaneous formulation of roche’s herceptin approved in switzerland for the treatment of her2-positive breast cancer.  Full Article

Roche confirms 2017 guidance irrespective of aphinity trial outcome
Wednesday, 1 Feb 2017 11:36am EST 

Roche Holding Ag :Ceo says confirms 2017 guidance irrespective of outcome of aphinity trial.  Full Article

More From Around the Web

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

LONDON Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival.